Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Krystal Biotech (KRYS) Accumulated Depreciation & Amortization (2021 - 2025)

Historic Accumulated Depreciation & Amortization for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $31.3 million.

  • Krystal Biotech's Accumulated Depreciation & Amortization rose 4271.18% to $31.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $31.3 million, marking a year-over-year increase of 4271.18%. This contributed to the annual value of $31.3 million for FY2025, which is 4271.18% up from last year.
  • Per Krystal Biotech's latest filing, its Accumulated Depreciation & Amortization stood at $31.3 million for Q4 2025, which was up 4271.18% from $29.2 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Accumulated Depreciation & Amortization ranged from a high of $31.3 million in Q4 2025 and a low of $2.8 million during Q4 2021
  • For the 5-year period, Krystal Biotech's Accumulated Depreciation & Amortization averaged around $12.9 million, with its median value being $9.9 million (2023).
  • As far as peak fluctuations go, Krystal Biotech's Accumulated Depreciation & Amortization skyrocketed by 21632.55% in 2023, and later surged by 4271.18% in 2025.
  • Quarter analysis of 5 years shows Krystal Biotech's Accumulated Depreciation & Amortization stood at $2.8 million in 2021, then surged by 46.44% to $4.1 million in 2022, then surged by 216.33% to $12.8 million in 2023, then surged by 70.88% to $21.9 million in 2024, then soared by 42.71% to $31.3 million in 2025.
  • Its Accumulated Depreciation & Amortization was $31.3 million in Q4 2025, compared to $29.2 million in Q3 2025 and $26.7 million in Q2 2025.